Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 20/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.64 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5626746 | 0.94 | PTGER1 (0.88) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5628437 | 0.91 | PTGER1 (0.85) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL6168780 | 0.90 | PTGER1 (0.84) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5629508 | 0.90 | PTGER1 (1.00) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL6176032 | 0.86 | PTGER1 (0.67) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5630277 | 0.85 | PTGER1 (0.74) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5628509 | 0.83 | PTGER1 (1.00) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5627998 | 0.83 | PTGER1 (0.86) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5631647 | 0.83 | PTGER1 (1.00) | PTGER1CYP2C9 | |
| SCHEMBL5629744 | 0.83 | PTGER1 (0.86) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |